Literature DB >> 9144611

Orthostatic hypotension in spinal cord injured patients.

J Blackmer1.   

Abstract

Treatment of orthostatic hypotension is an important consideration for many patients with spinal cord injuries, especially those with an injury to the cervical cord. Delay in attainment of an upright sitting posture can cause a delay in the completion of rehabilitation. Although most trials of medications used in the treatment of orthostatic hypotension have been performed on non-spinal cord injured patients, this paper provides a review of both pharmacological and non-pharmacologic means of therapy. Normally, regulation of mean arterial pressure occurs through several different mechanisms; long-term control is via the renal system and short-term control is via the nervous system. These mechanisms will be discussed, as well as causes of orthostatic hypotension in spinal cord injured patients, and the normalization of blood pressure control which generally occurs to some degree following a spinal cord injury.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9144611     DOI: 10.1080/10790268.1997.11719471

Source DB:  PubMed          Journal:  J Spinal Cord Med        ISSN: 1079-0268            Impact factor:   1.985


  11 in total

1.  Potential risks of nitric oxide inhibition in spinal cord injury.

Authors:  Nosratola D Vaziri
Journal:  J Spinal Cord Med       Date:  2007       Impact factor: 1.985

Review 2.  Management of postural hypotension.

Authors:  M S Kochar
Journal:  Curr Hypertens Rep       Date:  2000-10       Impact factor: 5.369

3.  Comparison of coronary artery calcification scores and National Cholesterol Education program guidelines for coronary heart disease risk assessment and treatment paradigms in individuals with chronic traumatic spinal cord injury.

Authors:  Jesse A Lieberman; Flora M Hammond; Thomas A Barringer; H J Norton; David C Goff; William L Bockenek; William M Scelza
Journal:  J Spinal Cord Med       Date:  2011       Impact factor: 1.985

Review 4.  Decentralized cardiovascular autonomic control and cognitive deficits in persons with spinal cord injury.

Authors:  Jill M Wecht; William A Bauman
Journal:  J Spinal Cord Med       Date:  2013-03       Impact factor: 1.985

5.  Normalization of supine blood pressure after nitric oxide synthase inhibition in persons with tetraplegia.

Authors:  Jill M Wecht; Joseph P Weir; AnnMarie H Krothe; Ann M Spungen; William A Bauman
Journal:  J Spinal Cord Med       Date:  2007       Impact factor: 1.985

6.  Orthostatic responses to anticholinesterase inhibition in spinal cord injury.

Authors:  Jill M Wecht; Christopher M Cirnigliaro; Frank Azarelo; William A Bauman; Steven C Kirshblum
Journal:  Clin Auton Res       Date:  2015-04-28       Impact factor: 4.435

7.  Clinical treatment of orthostatic hypotension after spinal cord injury with training based on electric uprise bed coupled with remote ECG and BP monitor.

Authors:  Dantong Shen; Huai Huang; Hui Yuan; Xu Zhang; Min Li
Journal:  Med Sci Monit       Date:  2014-12-22

8.  Effect of Myoarchitectonic Spinolaminoplasty on Concurrent Hypertension in Patients With Cervical Spondylotic Myelopathy.

Authors:  Kazushige Itoki; Ryu Kurokawa; Tetsuro Shingo; Phyo Kim
Journal:  Neurospine       Date:  2018-03-28

9.  Epidural Spinal Cord Stimulation of Lumbosacral Networks Modulates Arterial Blood Pressure in Individuals With Spinal Cord Injury-Induced Cardiovascular Deficits.

Authors:  Sevda C Aslan; Bonnie E Legg Ditterline; Michael C Park; Claudia A Angeli; Enrico Rejc; Yangsheng Chen; Alexander V Ovechkin; Andrei Krassioukov; Susan J Harkema
Journal:  Front Physiol       Date:  2018-05-18       Impact factor: 4.566

10.  Beneficial Cardiac Structural and Functional Adaptations After Lumbosacral Spinal Cord Epidural Stimulation and Task-Specific Interventions: A Pilot Study.

Authors:  Bonnie E Legg Ditterline; Shelley Wade; Beatrice Ugiliweneza; Narayana Sarma Singam; Susan J Harkema; Marcus F Stoddard; Glenn A Hirsch
Journal:  Front Neurosci       Date:  2020-10-22       Impact factor: 4.677

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.